Loading
Trabectedin reduced the risk of progression by 45 percent compared with dacarbazine in previously treated liposarcoma and leiomyosarcoma, leading to its approval in the United States, though survival was not improved.
Phase 3 trial of 518 patients with advanced liposarcoma or leiomyosarcoma after an anthracycline and at least one other regimen randomised 2:1 to trabectedin or dacarbazine.
Median progression-free survival was 4.2 versus 1.5 months (hazard ratio 0.55) with benefit in both histologies and particularly in myxoid liposarcoma; median overall survival was 12.4 versus 12.9 months (not significant). Transaminase elevation and myelosuppression were the main toxicities.
Trabectedin is a standard later-line option for liposarcoma and leiomyosarcoma and is especially active in myxoid liposarcoma.
Shares Liposarcoma, Dacarbazine.
Shares Liposarcoma, Leiomyosarcoma.
Shares Liposarcoma, Leiomyosarcoma.
Shares Trabectedin, Leiomyosarcoma.
Shares Trabectedin, Leiomyosarcoma.
Shares Leiomyosarcoma, Dacarbazine.
Shares Dacarbazine, Journal of Clinical Oncology.